Form 4: Ocular Therapeutix Chief Development Officer Sells Shares to Cover Tax Obligations

Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc., sold 2,974 shares of common stock for $7.17 per share to satisfy tax withholding obligations related to RSU vesting, as part of a pre-arranged 10b5-1 plan.

Summary

• Peter Kaiser, the Chief Development Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of company common stock.
• The transaction involved the disposition of 2,974 shares of common stock on May 23, 2025.
• The shares were sold at a weighted average price of $7.17 per share, with individual sales ranging from $7.04 to $7.28.
• This sale was executed pursuant to a durable automatic sale instruction (Rule 10b5-1 plan) adopted by Mr. Kaiser on April 9, 2024.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) that occurred on May 22, 2025.
• The filing explicitly states that the sales do not represent a discretionary trade by the reporting person.
• Following this transaction, Peter Kaiser beneficially owns 207,104 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary sale of shares to cover tax obligations related to RSU vesting, which is a common practice and does not indicate a change in management's confidence or company performance.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically a 'sell-to-cover' action for tax purposes. Such transactions are common across all industries when executives' restricted stock units vest, and they typically do not reflect a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in company fundamentals or management's view on the stock.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Peter Kaiser, Chief Development Officer, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan